TIMP-1 via TWIST1 induces EMT phenotypes in human breast epithelial cells

Molecular Cancer Research

Volumn 12, Issue 9, 2014, Pages 1324-1333

  D'Angelo, Rosemarie Chirco ^a   Liu, Xu Wen ^a   Najy, Abdo J ^a   Jung, Young Suk ^a   Won, Joshua ^a   Chai, Karl X ^a   Fridman, Rafael ^a   Kim, Hyeong Reh Choi ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD63 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; FIBRONECTIN; MATRIX METALLOPROTEINASE; NERVE CELL ADHESION MOLECULE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG; VIMENTIN; CADHERIN; CD63 PROTEIN, HUMAN; NUCLEAR PROTEIN; TIMP1 PROTEIN, HUMAN; TWIST1 PROTEIN, HUMAN;

ARTICLE; BREAST EPITHELIUM; CELL ADHESION; CELL MOTILITY; CELL STRUCTURE; CELL SURVIVAL; CYTOSKELETON; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PHENOTYPE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; APOPTOSIS; BREAST TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

ANTIGENS, CD63; APOPTOSIS; BREAST NEOPLASMS; CADHERINS; CELL PROLIFERATION; CELL SURVIVAL; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TWIST TRANSCRIPTION FACTOR;

EID: 84907276388     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0105     Document Type: Article

References (48)

1. Kleiner DE Jr, Stetler-Stevenson WG. Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol 1993;5:891-7.
2. Wurtz SO, Schrohl AS, Mouridsen H, Brunner N. TIMP-1 as a tumor marker in breast cancer-an update. Acta Oncol 2008;47:580-90.
3. Moller Sorensen N, Vejgaard Sorensen I, Ornbjerg Wurtz S, Schrohl AS, Dowell B, Davis G, et al. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment. Scand J Gastroenterol 2008;43:774-86.
4. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006;25:99-113.
5. Logan SK, Garabedian MJ, Campbell CE, Werb Z. Synergistic transcriptional activation of the tissue inhibitor of metalloproteinases-1 promoter via functional interaction of AP-1 and Ets-1 transcription factors. J Biol Chem 1996;271:774-82.
6. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995;267:891-3.
7. Alexander CM, Howard EW, Bissell MJ, Werb Z. Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. J Cell Biol 1996;135: 1669-77.
8. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002;277:11069-76.
9. Docherty AJ, Lyons A, Smith BJ, Wright EM, Stephens PE, Harris TJ, et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985;318: 66-9.
10. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growthpromoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992;298:29-32.
11. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998;102:2002-10.
12. Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999; 59:6267-75.
13. Liu XW, Bernardo MM, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase- 1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 2003;278: 40364-72.
14. Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005;65: 898-906.
15. Jung YS, Liu XW, Chirco R, Warner RB, Fridman R, Kim HR. TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain. PloS ONE 2012;7:e38773.
16. Jung KK, Liu XW, Chirco R, Fridman R, Kim HR. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 2006;25:3934-42.
17. Egea V, Zahler S, Rieth N, Neth P, Popp T, Kehe K, et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/beta-catenin signaling. Proc Natl Acad Sci U S A 2012;109:E309-16.
18. Kang Y, Massague J. Epithelial-mesenchymal transitions: TWIST1 in development and metastasis. Cell 2004;118:277-9.
19. Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, slug, and TWIST1 and their clinical significance in human breast cancer. Ann Surg Oncol 2005;12:488-96.
20. Birchmeier C, Birchmeier W, Brand-Saberi B. Epithelial-mesenchymal transitions in cancer progression. Acta Anat 1996;156:217-26.
21. Vincent-Salomon A, Thiery JP. Host microenvironment in breast cancer development: epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 2003;5:101-6.
22. Taube ME, Liu XW, Fridman R, Kim HR. TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein. Oncogene 2006;25:3041-8.
23. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008;68:989-97.
24. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991;251:1451-5.
25. Lim SC, Lee MS. Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep 2002;9:915-28.
26. Boyer B, Valles AM, Edme N. Induction and regulation of epithelialmesenchymal transitions. Biochem Pharmacol 2000;60:1091-9.
27. Thisse B, el Messal M, Perrin-Schmitt F. The TWIST1 gene: isolation of a Drosophila zygotic gene necessary for the establishment of dorsoventral pattern. Nucleic Acids Res 1987;15:3439-53.
28. Berx G, Becker KF, Hofler H, van Roy F. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998;12:226-37.
29. Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE, et al. Aberrant methylation of the estrogen receptor and E-cadherin 50 CpG islands increases with malignant progression in human breast cancer. Cancer Res 2000;60:4346-8.
30. Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG. Methylation patterns of the E-cadherin 50 CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 2000;275:2727-32.
31. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 30 kinase/AKT pathways. Oncogene 2005;24:7443-54.
32. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003;63:2172-8.
33. Chen ZF, Behringer RR. TWIST1 is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev 1995;9:686-99.
34. Soo K, O'Rourke MP, Khoo PL, Steiner KA, Wong N, Behringer RR, et al. TWIST1 function is required for the morphogenesis of the cephalic neural tube and the differentiation of the cranial neural crest cells in the mouse embryo. Dev Biol 2002;247:251-70.
35. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, et al. TWIST1, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
36. Yousfi M, Lasmoles F, El Ghouzzi V, Marie PJ. TWIST1 haploinsufficiency in Saethre-Chotzen syndrome induces calvarial osteoblast apoptosis due to increased TNFalpha expression and caspase-2 activation. Hum Mol Genet 2002;11:359-69.
37. Hjiantoniou E, Iseki S, Uney JB, Phylactou LA. DNazyme-mediated cleavage of TWIST1 transcripts and increase in cellular apoptosis. Biochem Biophys Res Commun 2003;300:178-81.
38. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, et al. TWIST1 is a potential oncogene that inhibits apoptosis. Genes Dev 1999;13:2207-17.
39. Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT, et al. Identification of a novel function of TWIST1, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 2004;23:474-82.
40. Mironchik Y, Winnard PT Jr, Vesuna F, Kato Y, Wildes F, Pathak AP, et al. TWIST1 overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res 2005;65:10801-9.
41. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. TWIST1 transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007;67:1979-87.
42. Pulyaeva H, Bueno J, Polette M, Birembaut P, Sato H, Seiki M, et al. MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. Clin Exp Metastasis 1997;15:111-20.
43. Gilles C, Polette M, Birembaut P, Brunner N, Thompson EW. Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. Clin Exp Metastasis 1997;15:519-26.
44. Kuphal S, Wallner S, Schimanski CC, Bataille F, Hofer P, Strand S, et al. Expression of Hugl-1 is strongly reduced in malignant melanoma. Oncogene 2006;25:103-10.
45. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005;436:123-7.
46. Illman SA, Lehti K, Keski-Oja J, Lohi J. Epilysin (MMP-28) induces TGFbeta mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci 2006;119:3856-65.
47. Brown NL, Yarram SJ, Mansell JP, Sandy JR. Matrix metalloproteinases have a role in palatogenesis. J Dent Res 2002;81:826-30.
48. Hellman NE, Spector J, Robinson J, Zuo X, Saunier S, Antignac C, et al. Matrix metalloproteinase 13 (MMP13) and tissue inhibitor of matrix metalloproteinase 1 (TIMP1), regulated by the MAPK pathway, are both necessary for Madin-Darby canine kidney tubulogenesis. J Biol Chem 2008;283:4272-82.